In a poster presentation at ASCO 2018, authors shared data from a recent study which suggest that testing and modulating the composition of the gut microbiome can have a favorable effect on the impact of immune checkpoint inhibitors (ICIs) in patients with renal cell carcinoma (RCC). In the study, presented by Lisa Derosa, MD, from the Gustave Roussy Cancer Campus, Paris Saclay University in Villejuif, France, Derosa and her colleagues observed that specific microbiome restoration could increase the efficacy of immune checkpoint inhibitors.

Learn more by clicking here.